The Influence of SLCO1B1 (OATP1B1) Gene Polymorphisms on Atorvastatin Blood Concentrations and related Side Effects
碩士 === 國立陽明大學 === 藥理學研究所 === 100 === BACKGROUND: Statins are well established in the treatment of hypercholesterolaemia and the prevention of coronary artery disease. However, there is inter-individual variability in the response to statins, in terms of both lipid-lowering and adverse effects. The m...
Main Authors: | Yi-Kai Wang, 王怡凱 |
---|---|
Other Authors: | Yueh-Ching Chou |
Format: | Others |
Language: | zh-TW |
Published: |
2012
|
Online Access: | http://ndltd.ncl.edu.tw/handle/90480795186829688913 |
Similar Items
-
Pharmacogenetics of OATP Transporters Reveals That SLCO1B1 c.388A>G Variant Is Determinant of Increased Atorvastatin Response
by: Rosario D. C. Hirata, et al.
Published: (2011-09-01) -
Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.
by: Wenjun Ni, et al.
Published: (2010-11-01) -
SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability
by: Pablo Zubiaur, et al.
Published: (2021-03-01) -
EFFECT OF GENES SLCO1B1 AND MDR1 POLYMORPHISM ON ATORVASTATIN PHARMACOKINETICS AND PHARMACODYNAMICS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: RESULTS OF PILOT PHARMACOGENETICS STUDY
by: A. V. Semenov, et al.
Published: (2016-01-01) -
THE SLCO1B1 GENE POLYMORPHISM AND STATIN-INDUCED MYOPATHY IN RUSSIAN PATIENTS
by: V. I. Petrov, et al.
Published: (2014-10-01)